Media headlines about Tetraphase Pharmaceuticals (NASDAQ:TTPH) have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Tetraphase Pharmaceuticals earned a news impact score of 0.09 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 47.7170874598882 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Tetraphase Pharmaceuticals, Inc. (TTPH) Receives Average Recommendation of “Hold” from Brokerages (americanbankingnews.com)
- FY2017 EPS Estimates for Tetraphase Pharmaceuticals, Inc. Decreased by Analyst (TTPH) (americanbankingnews.com)
- Equities Analysts Set Expectations for Tetraphase Pharmaceuticals, Inc.’s Q3 2017 Earnings (TTPH) (americanbankingnews.com)
- Technical Review on Tetraphase Pharmaceuticals, Inc. (TTPH) – Wall Street Morning (wallstreetmorning.com)
- Tetraphase Pharmaceuticals, Inc. (TTPH) Rating Lowered to Hold at Zacks Investment Research (americanbankingnews.com)
Several equities research analysts have issued reports on TTPH shares. BMO Capital Markets reiterated an “outperform” rating and set a $13.00 target price (up from $12.00) on shares of Tetraphase Pharmaceuticals in a research report on Wednesday, July 26th. Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, July 6th. BidaskClub upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 22nd. Piper Jaffray Companies started coverage on shares of Tetraphase Pharmaceuticals in a research report on Monday, August 28th. They set an “overweight” rating and a $14.00 target price for the company. Finally, ValuEngine lowered shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $12.96.
Shares of Tetraphase Pharmaceuticals (NASDAQ TTPH) traded down 3.74% on Thursday, reaching $6.95. 336,746 shares of the company’s stock were exchanged. Tetraphase Pharmaceuticals has a one year low of $3.11 and a one year high of $9.93. The stock’s market cap is $354.82 million. The company’s 50 day moving average is $6.94 and its 200-day moving average is $7.27.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.07). Tetraphase Pharmaceuticals had a negative net margin of 2,092.20% and a negative return on equity of 79.79%. The firm had revenue of $1.59 million for the quarter, compared to analysts’ expectations of $1.54 million. During the same quarter in the prior year, the business posted ($0.47) EPS. The business’s quarterly revenue was up 28.2% on a year-over-year basis. On average, analysts anticipate that Tetraphase Pharmaceuticals will post ($2.85) EPS for the current year.
In other news, insider Jacques Dumas sold 17,500 shares of the business’s stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $6.00, for a total transaction of $105,000.00. Following the sale, the insider now owns 17,500 shares in the company, valued at $105,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.50% of the stock is owned by insiders.
WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Tetraphase Pharmaceuticals (TTPH) Share Price” was first posted by Stock Observer and is the property of of Stock Observer. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.thestockobserver.com/2017/10/12/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-tetraphase-pharmaceuticals-ttph-share-price.html.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.